DE602004016522D1 - Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin) - Google Patents

Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)

Info

Publication number
DE602004016522D1
DE602004016522D1 DE602004016522T DE602004016522T DE602004016522D1 DE 602004016522 D1 DE602004016522 D1 DE 602004016522D1 DE 602004016522 T DE602004016522 T DE 602004016522T DE 602004016522 T DE602004016522 T DE 602004016522T DE 602004016522 D1 DE602004016522 D1 DE 602004016522D1
Authority
DE
Germany
Prior art keywords
treatment
neoplasien
tslp
diagnosis
thymic stromal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004016522T
Other languages
English (en)
Inventor
Martin Oft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE602004016522D1 publication Critical patent/DE602004016522D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602004016522T 2003-07-18 2004-07-16 Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin) Active DE602004016522D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48826303P 2003-07-18 2003-07-18
PCT/US2004/022928 WO2005007186A1 (en) 2003-07-18 2004-07-16 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin

Publications (1)

Publication Number Publication Date
DE602004016522D1 true DE602004016522D1 (de) 2008-10-23

Family

ID=34079411

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004016522T Active DE602004016522D1 (de) 2003-07-18 2004-07-16 Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)

Country Status (17)

Country Link
US (3) US20050048061A1 (de)
EP (1) EP1651247B1 (de)
JP (3) JP5436753B2 (de)
AT (1) ATE407691T1 (de)
AU (1) AU2004257781B2 (de)
CA (1) CA2532595A1 (de)
CY (1) CY1108645T1 (de)
DE (1) DE602004016522D1 (de)
DK (1) DK1651247T3 (de)
ES (1) ES2313076T3 (de)
HR (1) HRP20080617T3 (de)
MX (1) MXPA06000659A (de)
NZ (1) NZ544456A (de)
PL (1) PL1651247T3 (de)
PT (1) PT1651247E (de)
SI (1) SI1651247T1 (de)
WO (1) WO2005007186A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029581A1 (en) 1998-11-13 2000-05-25 Immunex Corporation Human tslp dna and polypeptides
ES2422879T3 (es) 2001-07-23 2013-09-16 Immunex Corporation Linfopoyetina estromal tímica humana modificada
SI1651247T1 (sl) * 2003-07-18 2009-02-28 Schering Corp Zdravljenje in diagnoza neoplazem z uporabo timusnega stromalnega limfopoietina
EP1777523A1 (de) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) In-vitro-Verfahren zur Prognose einer Tumorprogression und des Ergebnisses bei einem Patienten sowie Mittel zur Durchführung dieses Verfahrens
SE532251C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
WO2008076255A2 (en) * 2006-12-14 2008-06-26 Schering-Plough Ltd. Canine thymic stromal lymphopoietin protein and uses thereof
KR20100034015A (ko) * 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2213682A1 (de) 2009-01-30 2010-08-04 Institut Curie TSLP fördert Immunevasion und Persistenz von Viren
GB0918782D0 (en) * 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
WO2012001889A1 (ja) * 2010-06-28 2012-01-05 国立大学法人東北大学 Tslpを恒常的に高発現する細胞、及び前記細胞を利用したtslp調節剤のスクリーニング方法
US20120020960A1 (en) * 2010-07-26 2012-01-26 Baylor Research Institute Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer
WO2014162007A2 (en) 2013-04-04 2014-10-09 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
WO2018156649A1 (en) * 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
EP3606548A4 (de) * 2017-04-04 2021-03-24 Loma Linda University Biologisches präparat zur behandlung von krebs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
EP1115867A1 (de) 1998-09-21 2001-07-18 Schering Corporation Menschliche interleukin-b50. therapeutische verwendungen
WO2000029581A1 (en) * 1998-11-13 2000-05-25 Immunex Corporation Human tslp dna and polypeptides
EP2077279B1 (de) * 2000-06-28 2012-09-05 Amgen Inc. Thymic Stromal Lymphopoietin Rezeptor Moleküle und Verwendungen davon
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
CA2429343A1 (en) * 2000-11-17 2002-08-01 Hyseq, Inc. Nucleic acids and polypeptides
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
ES2422879T3 (es) * 2001-07-23 2013-09-16 Immunex Corporation Linfopoyetina estromal tímica humana modificada
EP2077277A1 (de) 2002-02-01 2009-07-08 Schering Corporation "Verwendung von Säuger-Zytokin; verwandte Reagenzien"
US20040022813A1 (en) * 2002-08-05 2004-02-05 Jean-Claude Bystryn Shed antigen vaccine with dendritic cells adjuvant
SI1651247T1 (sl) * 2003-07-18 2009-02-28 Schering Corp Zdravljenje in diagnoza neoplazem z uporabo timusnega stromalnega limfopoietina

Also Published As

Publication number Publication date
US20050048061A1 (en) 2005-03-03
EP1651247A1 (de) 2006-05-03
JP2007314547A (ja) 2007-12-06
JP5436753B2 (ja) 2014-03-05
CA2532595A1 (en) 2005-01-27
DK1651247T3 (da) 2009-01-12
PT1651247E (pt) 2008-12-15
MXPA06000659A (es) 2006-03-30
US8822405B2 (en) 2014-09-02
CY1108645T1 (el) 2014-04-09
ES2313076T3 (es) 2009-03-01
US20100015132A1 (en) 2010-01-21
EP1651247B1 (de) 2008-09-10
SI1651247T1 (sl) 2009-02-28
JP2007534623A (ja) 2007-11-29
JP2011236252A (ja) 2011-11-24
NZ544456A (en) 2009-02-28
WO2005007186A1 (en) 2005-01-27
PL1651247T3 (pl) 2009-04-30
AU2004257781A1 (en) 2005-01-27
HRP20080617T3 (en) 2009-01-31
ATE407691T1 (de) 2008-09-15
US20140370025A1 (en) 2014-12-18
AU2004257781B2 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
HRP20080617T3 (en) Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
DK1601694T3 (da) Anvendelser af IL23-antagonister, relaterede reagenser
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
DE502005009908D1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
TW200722437A (en) Anti-TrkB monoclonal antibodies and uses thereof
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
BRPI0519430A2 (pt) hormânio do crescimento humano modificado
EA201100158A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
EP1784639A4 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
ATE496636T1 (de) Verwendung von agonisten und antagonisten von interleukin-33 (il-33)
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
BRPI0507794A (pt) métodos de modular a atividade de il-23, reagentes relacionados
ATE505489T1 (de) Tgf-beta-1-spezifische antikörper
NO20064192L (no) Agonister og antagonister av P28, EB13 og WSX/TCCR til behandling av immunforstyrrelser
ATE500276T1 (de) Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
DE602006010187D1 (de) Einzelsequenzhybridisierungssonden
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
DE60336504D1 (de) 4-hydroxypiperidin-derivate zur verwendung als antimycobakterielle mittel
ATE299739T1 (de) Neurokinin b vorläufer aus menschlicher plazenta
ATE478095T1 (de) Konjugate mit einem für die ed-b-domäne von fibronectin spezifischen antikörper, und deren verwendung zum nachweis und zur behandlung von tumoren
DE602004006566D1 (de) Verfahren zur Diagnose und Behandlung von Metastasen und dafür nützliche Zusammensetzung
UA40336A (uk) Спосіб хірургічного лікування екстрапірамідних гіперкінезів у хворих із церебросудинною патологією
SE0301724D0 (sv) Substances for use in the treatment of beta-cell dependent diabetes, methods and kits for identifying the substances

Legal Events

Date Code Title Description
8364 No opposition during term of opposition